Literature DB >> 14556920

Frequent methylation of p16INK4A and p14ARF genes implicated in the evolution of chronic myeloid leukaemia from its chronic to accelerated phase.

E Nagy1, Z Beck, A Kiss, E Csoma, B Telek, J Kónya, E Oláh, K Rák, F D Tóth.   

Abstract

The frequency and mechanism of p16(INK4A) and p14(ARF) gene alterations were studied in cell samples from 30 patients with Philadelphia (Ph) chromosome-positive chronic myeloid leukaemia (CML), both at diagnosis and at the onset of the accelerated phase (AP) of the disease. No alterations in the p16(INK4A) or p14(ARF) genes were found in any of the chronic phase (CP) samples. DNA sequencing analyses detected p16(INK4A) or p14(ARF) mutations in 17 AP samples. All mutations were heterozygous without loss of the other allele. Aberrant methylation of the p16(INK4A) or p14(ARF) promoters was found in 14 of 30 AP samples. The most common situation was the simultaneous methylation of both promoters. Our data indicate that p16(INK4A) and p14(ARF) are primary targets for inactivation by promoter methylation in the acceleration of CML. Transcriptional silencing of the p16(INK4A) and p14(ARF) genes may be important in the conversion of CML from the CP to the AP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14556920     DOI: 10.1016/s0959-8049(03)00552-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  14 in total

Review 1.  Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Authors:  Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

2.  Frequent DAP kinase but not p14 or Apaf-1 hypermethylation in B-cell chronic lymphocytic leukemia.

Authors:  C S Chim; T K Fung; K F Wong; J S Lau; R Liang
Journal:  J Hum Genet       Date:  2006-08-03       Impact factor: 3.172

Review 3.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

4.  Aberrant Expression of p14ARF in Human Cancers: A New Biomarker?

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Tumor Microenviron       Date:  2019-02-04

5.  The BMI1 polycomb protein represses cyclin G2-induced autophagy to support proliferation in chronic myeloid leukemia cells.

Authors:  L Mourgues; V Imbert; M Nebout; P Colosetti; Z Neffati; P Lagadec; E Verhoeyen; C Peng; E Duprez; L Legros; N Rochet; V Maguer-Satta; F-E Nicolini; D Mary; J-F Peyron
Journal:  Leukemia       Date:  2015-04-30       Impact factor: 11.528

6.  Frequency of genetic and epigenetic alterations of p14ARF and p16INK4A in head and neck cancer in a Hungarian population.

Authors:  Andrea Kis; Tímea Zsófia Tatár; Tamás Gáll; Róbert Boda; Ildikó Tar; Tamás Major; Pál Redl; Lajos Gergely; Krisztina Szarka
Journal:  Pathol Oncol Res       Date:  2014-04-09       Impact factor: 3.201

Review 7.  miRNAs as Biomarkers in Chronic Myelogenous Leukemia.

Authors:  Kasuen Kotagama; Yung Chang; Marco Mangone
Journal:  Drug Dev Res       Date:  2015-08-18       Impact factor: 4.360

8.  Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma.

Authors:  Chor-Sang Chim; Raymond Liang; Tsz-Kin Fung; Chi-Lung Choi; Yok-Lam Kwong
Journal:  J Clin Pathol       Date:  2007-06       Impact factor: 3.411

Review 9.  Therapeutic targets in the ARF tumor suppressor pathway.

Authors:  Anthony J Saporita; Leonard B Maggi; Anthony J Apicelli; Jason D Weber
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

10.  Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.

Authors:  John Mascarenhas; Nitin Roper; Pratima Chaurasia; Ronald Hoffman
Journal:  Clin Epigenetics       Date:  2011-07-09       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.